SGMT Insider Trading Activity and SEC Form 4 Filings
SGMT insider trading summary
Over the past 12 months, insiders at Sagimet Biosciences Inc. (SGMT) reported 10 sales worth $4.9M by 5 insiders and no open-market purchases on SEC Form 4. Net insider selling was $4.9M.
Latest SGMT insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 14, 2026 | George Kemble | Insider | Sell | $3.6M (350,987 @ $10.23) |
| Aug 11, 2026 | George Kemble | Insider | Sell | $201K (20,206 @ $9.95) |
| Jul 20, 2026 | David Happel | President & CEO | Sell | $497K (64,051 @ $7.76) |
| Jul 20, 2026 | Elizabeth Rozek | Chief Legal & Admin. Officer | Sell | $82K (10,545 @ $7.76) |
| Jul 20, 2026 | George Kemble | Insider | Sell | $141K (18,844 @ $7.46) |
| Feb 10, 2026 | Elizabeth Rozek | Chief Legal & Admin. Officer | Sell | $14K (2,622 @ $5.36) |
| Feb 10, 2026 | Eduardo Bruno Martins | Chief Medical Officer | Sell | $20K (3,640 @ $5.36) |
| Feb 10, 2026 | Thierry Chauche | Chief Financial Officer | Sell | $7K (1,312 @ $5.36) |
| Feb 10, 2026 | David Happel | President & CEO | Sell | $65K (12,101 @ $5.36) |
| Nov 20, 2025 | George Kemble | Executive Chairman | Sell | $290K (37,688 @ $7.69) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.